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Abstract 
Human cytochrome P450 (CYP) 2A6 enzyme has been proposed to play a role in cellular 
defence against chemical-induced oxidative stress. The encoding gene is regulated by various 
stress activated transcription factors. This paper demonstrates that p53 is a novel 
transcriptional regulator of the gene. Sequence analysis of the CYP2A6 promoter revealed six 
putative p53 binding sites in a 3 kb proximate promoter region. The site closest to 
transcription start site (TSS) is highly homologous with the p53 consensus sequence. 
Transfection with various stepwise deletions of CYP2A6-5’-Luc constructs—down to -160 bp 
from the TSS—showed p53 responsiveness in p53 overexpressed C3A cells. However, a 
further deletion from -160 to -74 bp, including the putative p53 binding site, totally abolished 
the p53 responsiveness. Electrophoretic mobility shift assay with a probe containing the 
putative binding site showed specific binding of p53. A point mutation at the binding site 
abolished both the binding and responsiveness of the recombinant gene to p53. Up-regulation 
of the endogenous p53 with benzo[α]pyrene—a well-known p53 activator—increased the 
expression of the p53 responsive positive control and the CYP2A6-5’-Luc construct 
containing the intact p53 binding site but not the mutated CYP2A6-5’-Luc construct. Finally, 
inducibility of the native CYP2A6 gene by benzo[α]pyrene was demonstrated by dose-
dependent increases in CYP2A6 mRNA and protein levels along with increased p53 levels in 
the nucleus. Collectively, the results indicate that p53 protein is a regulator of the CYP2A6 
gene in C3A cells and further support the putative cytoprotective role of CYP2A6. 
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Introduction 
Human cytochrome P450 (CYP) 2A6 is a key enzyme responsible for the metabolism 
of nicotine and coumarin (review in Abu-Bakar et al., 2013). It can also metabolically 
activate tobacco-specific nitrosamines (Yamazaki et al., 1992). The bile pigment bilirubin 
(BR) has been suggested to be the endogenous substrate for CYP2A6 (Abu- Bakar et al., 
2012). The enzyme is predominantly expressed in the liver and commonly found in sex 
steroid-responsive tissues such as breast, ovary, uterus, testis, and adrenal gland (Nakajima et 
al., 2006), lung, nasal mucosa, oesophagus, trachea and skin (Janmohamed et al., 2001; 
Koskela et al., 1999; Su et al., 1996).  
The CYP2A6 expression is induced by structurally unrelated chemicals that are toxic to 
the liver, such as pyrazole, aminotriazole, griseofulvin and cobalt chloride (Donato et al., 
2000). It is also induced in fatty, inflamed and cirrhotic liver associated with microorganisms 
infections and harmful alcohol consumption (Fisher et al., 2009; Kirby et al., 1996; Niemela 
et al., 2000; Raunio et al., 1998; Satarug et al., 1996). Given the unrelated nature of the 
inducers, it is probable that CYP2A6 induction is not directly related to the nature of the 
inducing agents, but instead a consequence of specific cellular events associated with 
exposure to the inducers. This is indeed reflected in the complex regulation of CYP2A6, 
where it is controlled transcriptionally and/or post-transcriptionally, depending on the nature 
of cellular perturbations (Christian et al., 2004; Raunio & Rahnasto-Rilla, 2012).  
The post-transcriptional regulation of CYP2A6 is mediated by the interaction of 
heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) with the 3’-UTR of the CYP2A6 
mRNA and the transcript is stabilized when transcription is impaired by Actinomycin D 
(Christian et al., 2004). The up-regulation of CYP2A6 can also be achieved by protein 
stabilization (Abu-Bakar et al., 2012). This is demonstrated in a study with HepG2 cells 
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where treatment with BR—an endogenous substrate for CYP2A6—increased the half-life of 
CYP2A6 protein but did not alter the CYP2A6 mRNA level (Abu-Bakar et al., 2012).  
The transactivation of CYP2A6 is regulated by transcription factors (TFs) involved in 
cellular homeostasis and cytoprotection. For example, TFs implicated in bile acid/steroid 
homeostasis and energy metabolism, such as pregnane-X-receptor (PXR), peroxisome 
proliferator-activated receptor ɤ coactivator 1α (PGC-1α) and estrogen receptor α (ERα) 
(Goodwin et al., 2003; Staudinger et al., 2001; Xie et al., 2001) mediate upregulation of 
CYP2A6 expression by interacting with the relevant response elements in the distal promoter 
of CYP2A6 (> -2400 bp) (Higashi et al., 2007; Itoh et al., 2006).  
Similarly, stress activated nuclear factor (erythroid-derived 2)-like 2 (Nrf2) mediates 
transcriptional activation of CYP2A6 by direct interaction with the antioxidant response 
element (ARE) at position -1212 of the 5’-flanking region of the gene (Yokota et al., 2011). 
The study indicates a potential role for CYP2A6 in adaptive response to cellular stress as 
Nrf2 is a key regulator of stress responsive genes. This is in agreement with the suggested 
role of CYP2A6 in the regulation of intracellular antioxidant capacity during oxidative stress 
(Abu-Bakar et al., 2013; Muhsain et al., 2015). 
Another key transcription factor in cellular defence regulation is the tumor suppressor 
protein, p53, which is activated by many cellular perturbations to regulate the transcription of 
various genes that encode products with pro-oxidant or antioxidant functions (review in Saha 
et al., 2015). Upon activation, p53 induces apoptosis to remove severely damaged cells 
(Zuckerman et al., 2009). If the damage is limited, p53 invokes cell-cycle arrest to activate 
DNA-repair pathways to correct the defects (Helton and Chen, 2007). A recent study 
demonstrated that p53 not only functions to remove or fix damaged cells but also regulates 
antioxidant mechanisms to prevent cell death (Nam and Sabapathy, 2011). It does this by 
directly upregulating transactivation of a stress responsive gene heme oxygenase 1 (HMOX1). 
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Nam and Sabapathy (2011) demonstrated that p53-dependent HMOX1 expression was 
specifically induced by oxidative stress, nitrosative stress, hypoxia, and endoplasmic 
reticulum stress but not by common chemotherapeutic DNA-damaging agents. Based on 
these findings and the fact that some of the p53 activators are also inducers of CYP2A6, we 
hypothesized that p53 could be involved in the regulation of CYP2A6 gene.  
In the present study we demonstrate that CYP2A6 is a direct target gene of p53 and 
describe the molecular mechanisms involved. The findings describe a novel mechanism by 
which unspecific cellular stress, such as DNA damage and transcriptional arrest—triggers of 
p53 activation—upregulated the CYP2A6.  
 
Materials and Methods 
Chemicals and antibodies. Benzo[α]pyrene (BaP), DMSO, PBS, dithiothreitol (DTT), 
phenylmethylsulfonyl fluoride (PMSF), MgCl2, KCl, KOH, NaCl, Hepes, EDTA, IGEPAL, 
cyclohexanediamine tetraacetic acid, Triton X-100, p-coumaric acid and luminol were 
purchased from Sigma-Aldrich (Sydney, NSW, Australia). Mouse monoclonal anti-p53 
antibody (sc-126), rabbit plyclonal anti-HNF4 (sc-8987) and A-431 whole cell lysate (sc-
2201) were obtained from Santa Cruz Biotechnology Inc. (Dallas, Texas, USA). Mouse 
monoclonal anti-CYP2A6 (ab56069) and anti-HMOX1 (ab13248), and rabbit polyclonal anti 
-β-actin (ab8227) were sourced from Abcam (Cambridge, UK). Goat anti-mouse and goat 
anti-rabbit antibodies conjugated with horseradish-peroxidase were from Thermo Fisher 
Scientific Inc. (Melbourne, Victoria, Australia). All cell culture consumables were sourced 
from Invitrogen (Scoresby, Victoria, Australia). 
 
Culturing and treatment of C3A cells. The C3A human hepatocellular carcinoma cells 
(ATCC, Manassas, VA, USA) were propagated in T75 flasks in William’s Medium E 
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containing 10% FBS, 1% Glutamax and 1% Penicillin-Streptomycin. Human breast cancer 
cell line, MCF-7, were grown in Dulbecco's Modified Eagle Medium supplemented with 
10% FBS, 1% Glutamax and 1% Penicillin-Streptomycin. The cells were maintained in a 
humidifier incubator at 37°C in 5% CO2 and were subcultured at least two times per week. 
Cells with passage number between 5 and 15 were used in all studies.  
 
Plasmids and transient transfection assays. The CYP2A6 5’-flanking region -2901/+9 was 
amplified from a human DNA sample using high-fidelity PCR polymerase and cloned in 
front of the luciferase cDNA in pGL3-basic vector (Promega, Madison, WI). The 5’-
truncated fragments of the CYP2A6 promoter were produced by PCR amplification using the 
cloned longer construct as template. The primers used for the amplification were listed in 
Table 1. Promoter constructs were co-transfected with either the human p53 expression 
plasmid (pcDNA3-hp53) (Christian et al., 2008) or the empty expression plasmid pcDNA3. 
The pGL4.38[luc2P/p53 RE/Hygro] vector (Promega, Madison, WI) was used as the positive 
control for the luciferase activity assay.  
 Polyethylenimine (PEI) (Polysciences Inc., PA, USA) was used to transiently transfect 
cultured cells with the various promoter constructs. PEI stock solution (1 μg/μl) was prepared 
by dissolving 100 mg of PEI in 100 ml of sterilised water at 50°C and pH adjusted to 7 with 
HCl. The solution was passed through a 0.22 μm filter (Millipore, USA) and stored at -80°C. 
The PEI solution was warmed up to room temperature before being added to DNA plasmid 
solution at DNA:PEI ratio of 1:2. The DNA-PEI mixture was then incubated at room 
temperature for 15 min before being added to each well of the 24-well plates. 
 Cells were seeded in 24-well plates (1.2 × 10
5
 cells/well) for 24 h. Thereafter, the cells 
were washed once in 500 µl PBS, followed by addition of 500 µl of fresh FBS-free medium 
to each well. The cells were then co-transfected with 0.1 µg of pMAX-GFP (transfection 
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control), 0.1 µg of pcDNA3 or pcDNA3-hp53, and 0.3 µg of CYP2A6-5’-Luc constructs.  
The transfected cells were incubated for 24 h in a humidifier incubator at 37°C in 5% CO2. 
Thereafter, the luciferase activity was measured (Britelite
TM
plus Reporter Gene Assay 
System, PerkinElmer, USA). Transfection under each condition was performed in quadruplet. 
The fluorescent and luminescence signals were captured on a FLUOstar Omega multimode 
microplate reader with automatic gain settings.  
 
BaP treatment of the transfected MCF-7 cells. Human breast cancer MCF-7 cells were 
seeded in 24-well plates at 1.2 × 10
5
 cells/well and 100 mm culture dish (Corning, USA) at 3 
× 10
6
 cells/well for 24 h. Cells in the 24-well plates were co-transfected with pMAX-GFP 
and pGL4.38[luc2P/p53 RE/Hygro] or CYP2A6-5’-Luc constructs at a fixed DNA:PEI ratio 
of 1:8. The amount of each plasmid used was 100 ng per well and 2.5 µg per dish. The cells 
were transfected for 4 h before being treated with various concentrations of BaP dissolved in 
DMEM containing 10% charcoal stripped FBS, 1% Glutamax, 1% Penicillin-Streptomycin, 
and 0.1% DMSO. Twenty four hours after treatment luciferase activity was measured and 
nuclei protein extracted.   
 
Isolation of nuclear and cytoplasmic proteins. Nuclear and cytoplasmic extracts from 
cultured cells were prepared as described previously (Abu-Bakar et al., 2007). Briefly, 5 × 
10
6
 cells in a 100 mm culture dish were washed and resuspended in 5 ml cold PBS. The cell 
suspension was centrifuged at 1600 x g for 10 min at 4
o
C. The resulting pellet was 
resuspended in 200 µl of buffer A (10 mM Hepes-KOH, pH 7.9, 1.5 mM MgCl2, 10 mM 
KCl, 0.5 mM DTT, 0.2 mM PMSF, 10µg/ml leupeptine, 0.4% IGEPAL) and kept on ice for 1 
h. Thereafter, the cell suspension was vortexed, homogenized and centrifuged at 12,000 x g 
for 10 min at 4
o
C. The supernatant containing cytoplasmic proteins was aliquoted and stored 
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at -80
o
C. The pellet containing nuclei was resuspended in 50 µl of cold buffer B (20 mM 
Hepes-KOH, pH 7.9, 25% glycerol, 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM EDTA, 0.5 mM 
DTT, 0.2 mM PMSF, 0.4% IGEPAL) and gently agitated with magnetic stirrer for 30 min at 
4
o
C. The suspension was homogenized and centrifuged at 15,000 x g for 15 min, at 4
o
C.  The 
supernatant containing nuclear proteins was diluted 1:1 with the dilution buffer (20 mM 
Hepes-KOH, pH 7.9, 15% glycerol, 0.2 mM EDTA, 0.5 mM DTT, 0.2mM PMSF), aliquoted 
and stored at -80
o
C. 
 
Protein analysis. Protein concentrations of the subcellular fractions were measured by the DC 
protein assay kit (Bio-Rad Laboratories, USA). The p53 protein and CYP2A6 apoprotein 
levels in the subcellular fractions were measured by Western immunoblotting. In brief, 30 µg 
of cytosolic or nuclei proteins were separated by 4%-15% SDS-polyacrylamide gel (Bio-Rad 
Laboratories, USA) electrophoresis. The proteins were electrophoretically transferred on to a 
Hybond ECL nitrocellulose membrane (Amersham Biosciences UK, Ltd) and blocked 
overnight in Tris-buffered saline containing 0.1% Tween 20 (TBS-T) and 5% non-fat milk. 
The membrane was then incubated with the relevant antibody (1:500 dilution) for 2 h, 
washed with TBS-T, and incubated for 1 h with horseradish peroxidase-conjugated goat anti-
mouse IgG (1:3000 dilution).  After further washing with TBS-T, the membrane was 
incubated with luminol solution (1 M Tris pH 8.5, 90 mM p-coumaric acid, 250 mM luminol, 
and 3% H2O2) for 5 min and immunoreactive bands were visualized and captured by the 
ChemiDoc
TM
 MP imaging system (Bio-Rad Laboratories, USA).  
  
RNA extraction and mRNA analysis. Total cellular RNA was extracted from C3A cells with 
TRIzol reagent (Gibco, Australia) in accordance with the manufacturer’s protocol. Total 
RNA was treated with RNA-free DNAse prior to mRNA measurement by quantitative real 
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time RT-PCR. One microgram of total RNA from the control and treated C3A cells was used 
to synthesise first-strand cDNA with the Invitrogen SuperScript
®
III First-Strand Synthesis kit 
(Life Technologies, Vic, Australia). Two microliters of the cDNA solution was used as 
template in 20 µl PCR mixture containing 10 µl of the 2 X iQ SYBR Green Supermix (Bio-
Rad Laboratories, USA) and 2 µl of each reverse and forward primers (Table 1) (0.2 µM final 
concentration). The PCR mixtures were incubated at 95
o
C for 3 min, followed by 40 cycles 
of 95
o
C for 20 s and 63.2
o
C (for CYP2A6 primers), 65.7
o
C (for HMOX1 primers),  or 60.4
o
C 
(for GAPDH primers) for 1 min in Corbett RotorGene 3000 (QIAGEN, Germany). The 
specificity of the PCR products was confirmed by melt curve analysis and amplicon size 
(2.5% agarose gel electrophoresis). 
 
Electrophoretic mobility shift assay. Double-stranded oligonucleotide corresponding to the -
149 to -55 (Probe 1) region of the 5’-flanking CYP2A6 promoter were generated by 
polymerase chain reaction (PCR). The probe was amplified by the primer 1 and primer 2 
(Table 1). The primers, double-stranded oligonucleotides of putative and consensus p53RE 
and of the -127 to -98  region of the 5’-flanking CYP2A6 promoter (Probe 2) were obtained 
from Sigma-Genosys (Sydney, Australia). The PCR product was purified by using the QIA 
quick PCR purification kit (QIAGEN, Germany) in accordance with the manufacturer’s 
protocol. The probes were labelled with digoxigenin on the 3’ end of the oligonucleotide 
using DIG gel shift kit (Roche, Germany).  Thereafter, 32 fmol/µl of digoxigenin-labelled 
probe was incubated with 16 µl of binding buffer and 4 µg of nuclei protein—extracted from 
C3A cells transfected with p53 expression plasmid—for 15 min at room temperature. In 
antibody shift assay, 1 µl of anti-p53, Nrf2 or HNF4 antibody was added to the reaction 
mixture and was incubated for 15 min. The samples were loaded to a pre-electrophoresed, 
non-denaturing 4-15% polyacrylamide gel in 0.5 × TBE buffer (44 mM Tris-HCl, pH 8, 44 
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mM boric acid, 1 mM EDTA). Samples were separated electrophoretically at 80V for 1 h and 
transferred to a positive-charged nylon membrane Hybond-N (Amersham Biosciences, UK, 
Ltd) by an electro-blotting device (Bio-Rad Laboratories, USA) set at 1 h at 30V, 300mA. 
Thereafter, the membrane was baked at 140
o
C for 15 min and crosslinked in a UV 
Stratalinker
TM
 1800 (Integrated Sciences, Australia) at 120 mJ. The membrane was briefly 
rinsed for 3 min in washing buffer and was blocked in blocking solution for 30 min before 
immunological detection. The digoxigenin-labelled probes on the membrane were detected 
by incubating the membrane with an anti-digoxigenin-AP antibody (1:10,000). The 
chemiluminescence signals of the labelled probes were captured by ChemiDoc™ MP 
imaging system after applying the alkaline phosphatase substrate CSPD on the membrane. 
Competition binding assay was performed to validate the specificity of protein–DNA 
interactions. In this assay, 125-fold molar excess of unlabelled oligonucleotides was added to 
the incubation mixture. The double-stranded consensus p53 oligonucleotide 
5’AGACATGCCTAGACATGCCT 3’ (underlined bases are core sequence) was used as 
positive control for p53 specific binding.  
 
Site directed Mutagenesis. The potential p53 sites on the proximal CYP2A6 promoter was 
analysed by site-directed mutagenesis. The core sequences of the putative p53RE 5’-
ATTCATGGTGGGGCATGTAG-3’ (core sequences, bold) was mutated to 5’-
ATTACCAGTGGGGATCCTAG-3’ (mutated sequences, underlined) by the two steps PCR. 
The CYP2A6 construct from -250 to the p53RE mutated sites was amplified from the 
template plasmid CYP2A6 5’ -437/+9 by priming with the forward primer CYP2A6 5’-250 
FW and reverse primer CYP2A6-p53mut (Table 1). The CYP2A6 construct from p53RE 
mutated site to +9 was amplified from the template plasmid CYP2A6 5’ -437/+9 by priming 
with the forward primer CYP2A6-p53mut and the reverse primer CYP2A6 5’+9 NheI RV 
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(Table 1). Equal amount of PCR products from the two reactions were mixed together, which 
acted as a template to amplify the mutated p53RE. The CYP2A6-160/+9 construct containing 
the mutated p53RE was generated by priming with the forward CYP2A6 5’ -160 KpnI FW 
and the reverse primer CYP2A6 5’+9 NheI RV (Table 1). The p53RE mutated CYP2A6 
construct was ligated to the pGL3-basic plasmid. The validity of the mutated p53RE on the 
CYP2A6 5’ -160/+9 construct was confirmed by gene sequencing.   
 
Statistical analysis. Two group comparisons were analysed by Student’s t test. Multiple 
group comparisons were done with one-way analysis of variance (ANOVA) followed by the 
least significant difference post hoc test. Differences were considered significant when p < 
0.05.  
 
Results 
CYP2A6 putative p53REs are responsive to p53  
Putative TF binding site search with ―MatInspector‖ (http://www.genomatix.de/) 
revealed regions of the CYP2A6 promoter with high sequence similarity with the 10 bp 
consensus p53RE [5’-RRRC(A/T)(T/A)GYYY-3’], where ―R‖ represents purine and ―Y‖ 
represents pyrimidine (el-Deiry et al., 1992). Five putative distal sites were identified at 
positions -2582, -2461, -2208, -1617, -1056, and one putative proximal site at position -122 
(Fig. 1A). We then tested p53 involvement in transcriptional regulation of the CYP2A6 gene 
by transiently transfecting C3A cells with luciferase reporter plasmid containing either the 
proximal (CYP2A6-5’-437/+9-Luc) or distal (CYP2A6-5’-2901/+9-Luc) CYP2A6 promoter 
region. The cells were co-transfected with p53 expression plasmid (pcDNA3-hp53) or empty 
control plasmid (pcDNA3). C3A cells were preferred over other cell lines because p53 
overexpression was the strongest in C3A compared with HepG2 and MCF-7, and because it 
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was challenging to produce consistent induction of the CYP2A6-Luc constructs in the HepG2 
cells (Supplementary Figure1). 
Figure 1B shows that the p53 protein levels in cells co-transfected with the pcDNA3-
hp53 plasmid were significantly higher than in the control cells (pcDNA3). The p53 co-
transfection induced the distal CYP2A6-5’-2901/+9-Luc construct by ~4-fold relative to the 
control, which is similar to the fold induction observed in the positive control cells 
(transfection with consensus p53RE-Luc construct) (Fig. 1C). The induction was weaker with 
the proximal CYP2A6-5’-437/+9-Luc construct, by about 2.4-fold relative to the control (due 
partly to the elevated control levels) (Fig. 1C). No significant luciferase activity was observed 
in cells transfected with the pGL3-basic plasmid (negative control) (Fig. 1C). These 
observations suggest that both the proximal and distal regions of the CYP2A6 promoter are 
responsive to p53.  
We note that in normal cells—where p53 was not overexpressed (opened bar)—the 
luciferase activity of the distal promoter was significantly weaker than that of the proximal 
promoter (Fig 1C). For this reason and the fact that luciferase activity of the proximal 
promoter was almost equal to that of the positive control in p53 overexpressed cells, we 
focused on describing the functionality of this site and its significance in the regulation of the 
CYP2A6 gene.  
It is also noted that the activity of the distal promoter (-2901-LUC construct) is 
substantially lower than the vector control (p53RE-LUC) in both normal and p53-
overexpressed cells. This suggests presence of suppressor region(s) upstream the CYP2A6 
promoter, which is confirmed by previous studies (Higashi et al., 2007; Itoh et al., 2006; 
Pitarque et al., 2005). 
 
Proximal p53RE mediates p53 response of the CYP2A6 gene. 
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A series of 5’-truncated proximal CYP2A6 promoter-luciferase reporter plasmids were 
constructed and transfected into the C3A cells. The cells were then co-transfected with p53 
expression plasmid (pcDNA-hp53) or empty control plasmid (pcDNA3). P53 co-transfection 
up-regulated the CYP2A6-5’-437/+9-Luc construct 2.5-fold relative to control (Fig. 2A). A 
similar response was detected with the series of constructs equal to or longer than -160 bp but 
not with the shorter construct (-74 bp) (Fig. 2A). This suggests that the p53RE is located in 
the region from -160 to -74, which is in agreement with the MatInspector TF binding site 
search that revealed one putative p53RE at position -122 (Fig. 1A). This putative p53RE 
contains the two copies of p53 binding core sequence of the consensus p53RE, ―CATG‖ (Fig. 
2B, bold letters), however, the satellite sequence of the putative p53RE is different from that 
of the consensus p53RE (Fig. 2B). 
To establish the functional significance of the putative binding site, we assessed the 
luciferase expression after mutating the site, followed by assessment of p53 binding activity 
by way of electrophoretic mobility shift assay (EMSA).   
The core sequence, CATG, critical for p53 binding was mutated in the -122 bp site of 
the CYP2A6-5’-160/+9-Luc and CYP2A6-5’-2901/+9-Luc constructs to ACCA. The mutant 
constructs were then co-transfected with the p53 expression plasmid into the C3A cells. As 
expected, p53 co-transfection induced luciferase expression driven by the two constructs by 
about 2.6- to 3.9-fold relative to control (Fig. 2C). Point mutation at the core binding 
sequence dramatically reduced the p53 response of both the proximal and distal promoter 
activity (Fig. 2C), which suggests that the core binding sequence within the putative p53RE 
element at the -122 bp site is crucial in mediating the response.  
To confirm that the observed response was due to direct interaction of p53 with the 
putative site, EMSA was performed with nuclei fractions from C3A cells transfected with 
p53 expression plasmid using three oligonucleotide probes. Probe 1 is a longer 
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oligonucleotide containing the putative binding site from -149 to -55 bp (Fig. 3A). Probe 2 is 
a shorter oligonucleotide spanning the putative site from -127 to -98 bp. The third probe 
(Probe1Mut) is the longer oligonucleotide with the core sequence, CATG, critical for p53 
binding, mutated to ACCA. 
As shown in Fig. 3B, the transfection produced a substantial amount of p53 in the 
nucleus. Two distinct DNA-protein complexes were formed when Probe 1 was incubated 
with the C3A nuclear extract (Fig. 3C, lane 2). The lower complex (closed arrow) was super-
shifted with an anti-p53 antibody (Fig. 3C, lane 3), indicating that the DNA-protein complex 
contains p53. In the competitive assays, both complexes were competed out by a 125-fold 
excess of the unlabelled Probe 1 (S) (Fig. 3C, lane 4, closed and opened arrows). However, 
only the lower complex was competed out by increasing concentrations of the unlabelled 
consensus p53RE oligonucleotide (C) (Fig. 3C, lanes 5-7, closed arrow). The results suggest 
presence of p53 in the lower complex and indicate that a protein other than p53 is forming the 
higher complex (opened arrow) with Probe 1.   
Indeed, detailed analysis of the probe sequence revealed a putative binding site for 
hepatocyte nuclear factor 4α (HNF4α) (Fig. 3A, opened line square). Incubation with anti- 
HNF4α antibody shifted the migration of the higher complex (opened arrow) (Fig. 3C, lane 
8), confirming the presence of HNF4α. 
We included two other controls in the analysis to confirm specific binding of p53 and 
HNF4α. Migrations of the two complexes were not shifted by an anti-Nrf2 antibody (Fig. 3C, 
lane 9, closed and opened arrows) and the smaller complex was not formed with the mutated 
Probe 1 (Fig. 3C, lane 10).  To further confirm p53 specific binding, nuclei proteins were 
incubated with the shorter Probe 2, which contains only the putative p53 binding site. As 
expected, only one DNA-protein complex was formed with Probe 2 (closed arrow) (Fig. 3C, 
lane 12) and the migration of the complex (closed arrow) was shifted by anti-p53 antibody 
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but not with anti-HNF4α antibody (Fig. 3C, lanes 13 & 14). These observations strongly 
indicate specific interaction of p53 with the putative site at the proximal CYP2A6 promoter.  
Collectively, the EMSA analysis and the luciferase reporter gene assays demonstrate 
that the proximal CYP2A6 gene promoter contains a functional p53RE that potentially 
mediates transcriptional regulation of the gene. The functional p53RE appears to reside close 
to the previously described HNF4α binding site (Pitarque et al., 2005).   
 
Endogenous p53 activates expression of CYP2A6 
 To demonstrate that endogenous p53 can mediate expression of the CYP2A6-5’-
160/+9-Luc construct, as well as the transcriptional regulation of native CYP2A6 gene, we 
treated transfected MCF-7 and C3A cells with different concentrations of BaP, a known 
inducer of p53 (Biswal et al., 2003) for 24 h. BaP increased p53 protein levels in the nucleus 
of MCF-7 by 4-fold relative to control (Fig. 4A&B). Accordingly, BaP increased luciferase 
activity dose-dependently in cells transfected with either CYP2A6-5’-160/+9-Luc construct or 
reporter construct containing the consensus p53RE (pGL4.38-p53RE) (Fig. 4C). The 
response was totally abolished when the two copies of the CYP2A6 p53RE core sequence 
were mutated (pCYP2A6-5’-160/+9_p53mut-Luc) (Fig. 4C). These observations align with 
the results shown in Fig. 2C and Fig. 3, and indicate that the proximal CYP2A6 p53RE is 
responsive to induced endogenous p53.  
 It is unlikely that the induced luciferase activity was mediated by HNF4α as its level 
remained constant after BaP treatment (Fig. 4A&B). This is in agreement with previous 
observation that HNF4α regulates basal expression of CYP2A6 (Pitarque et al., 2005), and 
corresponds with our observation of constant luciferase activity in cells transfected with 
pCYP2A6-5’-160/+9_p53mut-Luc (Fig. 4C, closed triangle), where the HNF4α binding site is 
intact. 
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 Finally, BaP induced p53 dose-dependently in the nucleus of hepatocellular carcinoma 
cells (C3A) by 4-fold relative to control (Fig. 5A&C). This confirmed previous observations 
of BaP-dependent induction of p53 at mRNA and protein levels in human lung 
adenocarcinoma (A549), mouse hepatoma (Hepa-1c1c7) and fibroblast (NIG3T3) cell lines, 
as well as in mouse skin (Huang et al., 2012; Pei et al., 1999; Serpi & Vähäkangas, 2003). 
Importantly, recent investigation reported that BaP-induced CYP1A1 expression was 
regulated through p53 binding to a p53 response element in the CYP1A1 promoter region 
(Wohak et al., 2014). 
 It is noted that p53 induction by BaP aligned with dose-dependent increased of the 
CYP2A6 mRNA and apoprotein ranging from 2 to 4-fold relative to control (Fig. 5). Similar 
pattern of HMOX1 induction at mRNA and protein levels (another p53 target gene) was also 
observed (Fig. 5). This confirmed previous observations of BaP-dependent induction of 
HMOX1 expression in various human cell lines (Lee et al., 2009; Spink et al., 2002). 
These results together with our transfection data suggest that p53 mediates 
transcriptional activation of CYP2A6. The fact that p53 responsiveness was observed in three 
different cell lines (Suppl. Fig. 1) suggests that p53-dependent regulation of CYP2A6 is not 
cell specific. 
 
Discussion 
In the present study, we have for the first time demonstrated that the tumor suppressor 
protein, p53, is a regulator of the CYP2A6 gene. The finding provides novel insights into the 
complex regulation of CYP2A6 in response to cellular perturbations. It is not entirely 
surprising that p53 is a regulator of the CYP2A6 because the gene is known to be upregulated 
by conditions that commonly activate p53 (Abu-Bakar et al., 2013).  
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The presence of several putative p53REs on the CYP2A6 promoter suggests that p53 is 
an important regulator for the gene. However, the sequence similarity of the five putative 
p53REs at the distal CYP2A6 promoter with the consensus p53RE is not as high as that of the 
proximal CYP2A6 p53RE. The functional significance of the distal sites in regulating 
CYP2A6 expression is still obscured but our present observations supported by published data 
suggest a role for negative regulation. For instance, the basal expression of the distal CYP2A6 
promoter was significantly weaker than that of the proximal promoter (Fig 1C), which is in 
accordance with previous findings of potential suppressor region(s) upstream the CYP2A6 
promoter (Higashi et al., 2007;  Itoh et al., 2006; Pitarque et al., 2005). This region (up to -
2901) also contains functional Nrf2 binding sites (Yokota et al., 2011). Importantly, previous 
investigations have demonstrated direct interaction of p53 with Nrf2 response elements in 
suppressive regulation of stress responding genes including the Phase II metabolizing genes, 
NQO1 and GST-1 (Faraonio et al., 2006; Wakabayashi et al., 2010).  
It is thus plausible that interplay between p53 and Nrf2 at the distal promoter mediates 
suppression of CYP2A6 activation. Indeed, our preliminary observations in C3A cells 
indicated that overexpression of Nrf2 substantially supressed the p53-mediated response of 
the distal CYP2A6 promoter (manuscript in preparation), which contains a functional Nrf2 
binding site in close proximity with one of the putative p53REs. Inevitably, further work is 
warranted to confirm and understand in detail the possible Nrf2/p53 interaction on the 
CYP2A6 promoter and to investigate the functional significance of such interaction in 
CYP2A6 regulation, especially in the context of cellular perturbations. 
Our present data clearly shows that the putative p53RE at position -122 is crucial for 
the p53-dependent activation of the CYP2A6 because mutation of the core sequence of this 
site negated the activities of both proximal and distal promoters (Fig. 2C). Additionally, 
DNA-protein complex was not formed in gel shift assay with mutated p53RE probe (Fig. 3C, 
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lane 10). Furthermore, BaP, a transcriptional activator of p53 (Huang et al., 2012; Pei et al., 
1999), increased the proximal promoter (CYP2A6-5’-160/+9-Luc) activity dose-dependently, 
which is associated with dose-dependent increased of p53 protein (Fig. 4). The promoter 
activity induction was abolished when the p53RE at position -122 was mutated, i.e., the 
activity was maintained at basal level (Fig. 4C, closed triangle). It has been reported that the 
basal expression of CYP2A6 is governed by interplay between the transcription factors 
HNF4α, C/EBP α, C/EBPβ, and Oct-1 (Pitarque et al., 2005). The functional response 
elements for these transcription factors reside within the proximal promoter, spanning from -
112 to -61 (Fig. 1A). Thus, the plausibility of p53 interacting with some or all of these 
transcription factors in mediating transactivation of CYP2A6 cannot be ruled out by our 
present study and worthy of further investigation.  
We note that p53 also regulates other hepatic CYP genes involved in various metabolic 
pathways (Goldstein et al., 2013; Wohak et al., 2014). Eleven members from five different 
CYP subfamilies were induced by p53 (Goldstein et al., 2013). These include CYP4Fs and 
CYP19A1, enzymes that metabolize lipids and sex steroids, respectively (Goldstein et al., 
2013); and CYP21A2, a catalyst of glucocorticoid synthesis (Goldstein et al., 2013). These 
findings aligned with recent advancement in p53 research that acknowledges a critical role 
for p53 in regulating metabolism and maintaining cellular homeostasis (reviewed in Meek, 
2015). Additionally, p53 role in regulating drug metabolism was recognised in a recent work 
demonstrating direct p53 interaction on the p53REs of the CYP3A4 promoter, leading to 
transactivation of the gene (Goldstein et al., 2013). The p53-dependent activation of CYP3A4 
activity, the main enzyme responsible for clearing chemotherapeutics, was heightened 
following a chemotherapeutic stimulus (Goldstein et al., 2013). This observation indicates a 
systemic role for p53 in response to chemotherapy.  
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As CYP2A6 is not a major drug metabolizing enzyme, what is the physiological 
significance of p53-mediated transactivation of CYP2A6? At present, we have no conclusive 
explanation. However, as p53 plays an important role in maintaining cellular homeostasis 
(Meek, 2015), our findings—along with our previous observation that CYP2A6 efficiently 
oxidizes bilirubin (BR) to a less toxic biliverdin (Abu-Bakar et al., 2012)—indicate a 
potential role for the CYP2A6/p53 pathway in regulating bilirubin homeostasis maintenance.  
Furthermore, the observation that BaP—a carcinogen and transactivator of p53 (Pei et 
al., 1999)—concurrently induced CYP2A6 and HMOX1 expression (Fig. 5) suggests a 
potential role for CYP2A6 in cellular stress management. HMOX1 catalyses heme 
breakdown to biliverdin (BV), which is reduced to BR by biliverdin reductase. Bilirubin is an 
efficient scavenger of reactive oxygen and nitrogen species (Jansen et al., 2010; Liu et al., 
2003), but apoptotic at highly elevated concentrations (Rodrigues et al., 2002). Hence, 
activation of HMOX1 by p53 may lead to drastic elevation of BR concentration, which in 
turn, may overwhelm BR oxidant scavenging activity. Consequently, there is a need for a 
protective mechanism where BR is enzymatically oxidized to BV to curb its cytotoxicity, and 
to be reduced back to BR by biliverdin reductase when needed. CYP2A6 is potentially a good 
BR oxidase candidate under this condition as the Km for BR is within the subtoxic range 
(Abu-Bakar et al., 2012).  
Importantly, the proposition of CYP2A6 role in regulating BR homeostasis during 
chemical onslaught is further supported by a recent finding that BR elimination through 
conjugation was not elevated during the initial stage of cellular stress (Muhsain et al., 2015). 
Thus, transcriptional activation of CYP2A6 gene through p53 may function as a part of the 
cellular protection to re-establish BR homeostasis.  
We conclude that the novel findings presented in this paper implied important role for 
p53-mediated CYP2A6 and HMOX1 activation in regulating hepatic BR homeostasis. Given 
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the dual role of p53 in cytoprotection and apoptosis (Bensaad and Vousden, 2007), and the 
antioxidant and pro-apoptotic effects of BR (Jansen et al., 2010; Liu et al., 2003; Ollinger et 
al., 2007), it is of fundamental interest to understand how these seemingly contradictory 
events are related to the regulation of CYP2A6 and HMOX1. In this regard the possible 
interaction of Nrf2 and p53 in the regulation of CYP2A6 and HMOX1 might prove to be 
critical as has been shown for some other stress responsive genes (Faraonio et al., 2006; 
Wakabayashi et al., 2010). Understanding the molecular mechanisms of this interaction is the 
main focus of our current research. 
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Figure legends 
Figure 1: Putative p53REs at the CYP2A6 promoter and effect of p53 co-transfection on 
CYP2A6-5’-Luc construct activities in C3A cells. (A) A schematic representation of the 2.9 
kb CYP2A6 promoter region indicating the putative p53RE sites. The region spanning -112 to 
-61 contains overlapping response elements for DR-4, C/EBP, C/EBPβ, Oct-1, and HNF4 
(Pitarque et al., 2005). (B) The six putative p53 binding sites identified by MatInspector 
(http://www.genomatix.de/) and the p53 consensus sequence. Putative p53RE core sequences 
are shown in bold. R = purine; Y = pyrimidine.  (C) Western blot and densitometry of p53 
and β-actin (loading control) in C3A cells transfected with p53 expression plasmid (pcDNA-
hp53) and empty expression plasmid (pcDNA3). Each transfection was done in triplicate. 
Positive controls (+) = A-431 whole cell lysate for p53 and β-actin peptide. Relative p53 
expression (bar graph) = the intensity of p53 band relative to the intensity of β-actin band. (D) 
Effect of p53 co-transfection (pcDNA-hp53) on CYP2A6 distal and proximal driven 
luciferase activities. The firefly luciferase activities were measured 24 h after transfection. 
The measured activites were normalized against pMAX-GFP activity (transfection control 
plasmid). The values (n = 3) represent means ± S.D. p53 response of each reporter construct 
is indicated by -fold of activity to control co-transfection with pcDNA3. Mean difference is 
significant from control group at ***, p < 0.0005; **, p < 0.005; *, p < 0.05 (Student’s t test). 
 
Figure 2: Functionality test of the p53RE site on the proximal CYP2A6 promoter. (A) C3A 
cells were co-transfeceted with a series of 5’-truncated proximal CYP2A6 promoter-luciferase 
reporter plasmids and p53 expression plasmid (pcDNA3-hp53) or empty expression plasmid 
(pcDNA3). (B) The difference between putative and the consensus p53RE sequence. The 
boxed region contains the p53 binding core sequence. (C) Effect of p53 co-transfection on the 
mutated and wildtype CYP2A6 proximal and distal promoters activities. The potential 
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proximal p53 binding sites were mutated as described: TTCATG → TTACCA and 
GGCATG → GGATCC in CYP2A6-5’-160/p53mut-Luc, with the mutated bases in bold and 
the underlined bases representing the core sequence. The mutated and wildtype CYP2A6-5’-
Luc constructs were transfected to C3A cells and luciferase activities were measured 24 h 
after transfection.  The measured luciferase activities were normalized against co-transfected 
pMAX-GFP control plasmid activities. The values (n = 4) represent the means ± S.D. p53 
response of each reporter construct is indicated by -fold of activity to control co-transfection 
with pcDNA3. Mean difference is significant from control group at ****, p < 0.0001; **, p < 
0.005 (Student’s t test). 
 
Figure 3: EMSA analysis of p53 protein/CYP2A6 promoter interactions. (A) A schematic 
representation of the -160 to +1 region in the proximal CYP2A6 promoter. The closed arrows 
indicate orientation of the EMSA probe. The closed line square highlights sequence of the 
potential p53RE that was revealed by the MatInspector transcription factor binding site 
search (http://www.genomatix.de/). The opened line square highlights sequence of the 
HNF4α response element. (B) Western blot of p53 in the nuclei fractions of C3A cells 
transfected with p53 expression plasmid (pcDNA3-hp53).  Positive control (+) = A-431 
whole cell lysate. (C) EMSA blot. Nuclei proteins extracted from C3A cells transfected with 
pcDNA3-hp53 expression plasmid were incubated with digoxigenin-labelled probe the 
orientation of which was shown in (A). Probe 1 = 94 bp oligonucleotide containing the 
putative binding site from -149 to -55 bp. Probe 2 = 29 bp oligonucleotide spanning the 
putative binding site from -127 to -98 bp. Probe1Mut = Probe 1 with the core sequence, 
CATG, critical for p53 binding, mutated to ACCA. Lanes 1 & 11 represent incubation 
without nuclei proteins. Lanes 3 & 13 represent incubation with nuclei proteins and anti-p53 
antibody. Lane 9 represents incubation with nuclei proteins and anti-Nrf2 antibody. Lanes 8 
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& 14 represent incubation with nuclei proteins and anti- HNF4α antibody The reactions with 
nuclear extracts were competed with 125-fold excess of unlabelled probe (S) (lane 4) and 
descending concentrations of unlabelled consensus p53RE oligonucleotides (C) (lanes 5-7). 
Lane 10 represents incubation with nuclei proteins digoxigenin-labelled mutated probe. The 
closed arrow indicates smaller DNA-protein complex, and the opened arrow indicates bigger 
complex. The experiment was repeated three times, and similar results were obtained.  
 
Figure 4: Effect of benzo[a]pyrene (BaP) treatment on endogenous p53 activation and the 
proximal CYP2A6-luciferase construct activities in MCF-7 cells. The cells were transfected 
with pGL4.38-p53-Luc, CYP2A6-5’-160/+9-Luc, or CYP2A6-5’-160/p53mut-Luc for 4 h 
before being treated with various concentrations of BaP. Twenty-four hours after treatment 
nuclei proteins were extracted and luciferase activities were measured. (A) Western blot of 
p53, HNF4 and β-actin (loading control) in MCF-7 cells treated with various concentrations 
of BaP. Positive controls (+) = A-431 whole cell lysate for p53, HepG2 whole cell lysate for 
HNF4 and β-actin peptide. Each blot represents one of three blots (each blot showed the 
same pattern of induction). (B) Densitometry analysis of the Western blots. Fold induction = 
Relative p53 or HNF4 expression of treated samples / Relative p53 or HNF4 expression of 
control (0 µM BaP). Relative p53 or HNF4  expression = the intensity of p53 or HNF4  
band relative to the intensity of β-actin band. The values (n = 3) represent the means ± S.D. 
*Mean difference is significant from control group at p < 0.05 (Student’s t test). (C) Effect of 
BaP treatment on the luciferase activities of the putative CYP2A6 p53RE constructs. The 
firefly luciferase activities were measured 24 h after BaP treatment. The measured activites 
were normalized against pMAX-GFP activity (transfection control plasmid). The values (n = 
4) represent means ± S.D. *Mean difference is significant from control group at p < 0.05 
(Student’s t test). 
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Figure 5: Effect of BaP on endogenous p53, native CYP2A6 and HMOX1 expression in 
C3A cells. The cells were treated with various concentrations of BaP for 24 h. Thereafter 
total RNA, nuclei and cytosolic proteins were extracted. Quantitative real time RT-PCR was 
used to detect CYP2A6 and HMOX1 mRNA expression. (A) Western blot and densitometry 
of nuclei p53 and cytosolic CYP2A6 and HMOX1. β-actin was used as  loading control.  
Each blot represents one of three blots (each blot showed the same pattern of induction). 
Positive controls (+) = A-431 whole cell lysate for p53; peptides for β-actin and HMXO1; 
and recombinant CYP2A6 yeast microsomes. Fold induction = Relative protein expression of 
treated samples / Relative protein expression of control (0 µM BaP). Relative protein 
expression = the intensity of protein band relative to the intensity of β-actin band. (B) 
Migration of RT-PCR products in 2.5% agarose gel. Lane 1 = 50 bp DNA ladder. Lanes 2, 5 
and 8 are products from control cells; lanes 3, 6 and 9 are products from treated cells; and 
lanes 6, 7 and 10 are non-template control (NTC). GAPDH = housekeeping gene. The sizes 
of the PCR products align with the amplified regions by the primers. (C) Fold induction of 
p53 proteins, CYP2A6 and HMOX1 mRNA and protein in control and treated cells.  
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Figure 5 
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Table 1: Oligonucleotides used for amplifications in Real-time PCR, EMSA and site-directed 
mutagenesis experiments.  
Primers Sequences 
PCR Amplification: 
CYP2A6 5’ -368 KpnI FW 
CYP2A6 5’ -308 KpnI FW 
CYP2A6 5’ -250 KpnI FW 
CYP2A6 5’ -160 KpnI FW 
CYP2A6 5’ -74 KpnI FW 
CYP2A6 5’ +9 NheI RV 
CYP2A6 5’ -2901KpnI 
CYP2A6 5’ -437KpnI 
 
5’-GACGGTACCCCCCCAGATCCACAACTTTG-3’ 
5’-GACGGTACCGTGCTCCCCTATGCAAATATTC-3’ 
5’-GACGGTACCTCCTAAATCCACAGCCCTGC-3’ 
5’-GACGGTACCTTATCCTCCCTTGCTGGCTG-3’ 
5’-GACGGTACCATCAGCCAAAGTCCATCCCTC-3’ 
5’-GACGCTAGCGGTGGTAGTGGGATGATAGATG-3’ 
5’-GACGGTACCCATCCATCCGCTTCATCCTACAG-3’ 
5’-GACGGTACCCCTAAATGCACAGCCACACTTTG-3’ 
mRNA analysis: 
CYP2A6 NM_000762 
 
 
GAPDH NM_002046 
 
 
HMOX1 NM_002133 
 
F: 5’-AAGATCAGTGAGCGC TATGG-3’ 
R: 5’-TGAATACCACGCATAGCCT-3’  
Amplicon size: 178 bp 
    F: 5’- CATGAGAAGTATGACAACAGCCT-3’ 
   R: 5’-AGTCCTTCCACGATACCAAAGT-3’ 
Amplicon size: 113 bp 
F: 5’- CAGTGCCACCAAGTTCAAGC-3' 
R: 5’-GTTGAGCAGGAACGCAGTCTT-3' 
Amplicon size: 112 bp 
EMSA: 
Primer 1 
Primer 2 
 
5’-TGCTGGCTGTGTCCCAAGCTAG-3’ 
5’-GGGATGGACTTTGGCTGATTAC-3’ 
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Site-directed mutagenesis: 
CYP2A6-p53mut RV 
CYP2A6-p53mut FW 
 
5’-TAGGATCCCCACTGGTAATCCTGCCTAGCTTGG-3’ 
5’-ACCAGTGGGGATCCTAGTTGGGAGGTGAAATG-3’ 
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Highlights 
 
 CYP2A6 is an immediate target gene of p53 
 Six putative p53REs located on 3 kb proximate CYP2A6 promoter region  
 The region -160 bp from TSS is highly homologous with the p53 consensus sequence 
 P53 specifically bind to the p53RE on the -160 bp region 
 HNF4 may interact with p53 in regulating CYP2A6 expression 
